Contract Manufacturing, General

The companies will be integrated to form the newly-branded AGC Biologics, which will specialize in customized contract development and manufacturing organization services for the scale-up and cGMP manufacture of protein-based therapeutics.

The contract development and manufacturing organization has invested £30-million (US$42 million) at its Dundalk, Ireland site to offer expanded clinical trial services.

Flexibility, innovation, and creativity are critical for success in navigating the challenges facing the bio/pharmaceutical industry.

Attracting and retaining qualified bio/pharma experts demands a mix of recognition, rewards, and opportunities.

Amid business and regulatory uncertainty, bio/pharma experts reveal opinions on salary, recognition, and training.

Biocad and Sothema Labs have partnered to release cancer-treating biosimilars into the North African market.

Avista Pharma Solutions facility and equipment upgrades at its Longmont, Colorado facility support processing of potent compounds.

Almac Group will acquire BioClin Laboratories to expand Almac’s analytical service offerings.

Capsugel announced on Oct. 31, 2017 that it expanded clinical trial capabilities, as well as increased development and manufacturing capabilities for specialized drug products using liquid-filled hard capsule technology, at its Edinburgh facility in Scotland.

Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.

Predicted areas of growth include flow chemistry, fermentation, repatriation of overseas funds, oncology, and API/product integration, but the rate of change is unclear.

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.

Innovation speeds discovery, drives down costs, and improves productivity.

Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.

CMOs must embrace flexibility in their technology decisions and business arrangements.

As pharma models changed during the past 40 years, contract manufacturing capacity and services evolved to meet demand.

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate.

CMO executives are focusing on M&A activity, new business models, and fundraising limits.

The strategies of a innovation-driven CMO may be different than a capacity-driven CMO.

CMOs are working hard to improve performance by investigating new technologies for filtration and purification.

CMOs that offer an innovative service-oriented model will dominate the industry.

Bio/pharmaceutical contract service provides continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

PharmTech sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.

PharmSource report addresses how the opportunity for antibody drug conjugates measures up to the bio/pharma industry’s expectations.

Better process development is creating industry benchmarks for bioprocessing.

In the past, contract manufacturing organizations (CMOs) and contract development manufacturing organizations (CDMOs) have been focused most on achieving scale, reaching new clients in new geographic regions, and adding services that were previously unavailable, according to Gil Y. Roth, president of the Pharma and Biopharma Outsourcing Association. In a new report from CPhI, Roth explicates how consolidation has changed how CMOs position their services to clients and how CMOs add value to their businesses.

Despite emergence of biologics, small-molecule APIs benefit from industry growth.

PharmSource forecasts slow growth in a new report on the outlook for the contract manufacturing industry.

Suppliers indicate prices for single-use equipment are likely to increase.

What if the expanding pipeline isn’t enough to fuel CMO growth?